Therefore, the combined treatment with CDDP and specific inhibitors for IGF2BP3 or m6A, can be considered in a clinical setting to overcome intrinsic or acquired resistance to CDDP in bladder cancer patients. The gene discussed is IGF2BP3; the disease is urinary bladder cancer.